Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-023 Plus Ocrelizumab in Refractory Progressive Multiple Sclerosis
NCT06677710Phase 1Suspended
- Sponsor
- Indapta Therapeutics
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of IDP-023 in primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Indapta Therapeutics. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events (Part 1) at 1 year, Incidence of dose-limiting toxicities up to 21 days and 1 more. Started Jun 2026; status: suspended.
02
Drugs
IDP-023
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT06677710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06677710.